The Parkinson’s Progression Markers Initiative, built using Evidation Health’s research platform, aims to triple enrollment and recruit online participants.
The Parkinson’s Progression Markers Initiative, built using Evidation Health’s research platform, aims to triple enrollment and recruit online participants.
Former Dillon residents allege mold-infested apartment, unhealthy living conditions idsnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from idsnews.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
NEW YORK, May 20, 2021 /PRNewswire/ The Michael J. Fox Foundation for Parkinson s Research (MJFF) today announced that Deborah W. Brooks has been named CEO and Co-Founder of the nation s leading organization dedicated to finding a cure for Parkinson s disease (PD). She takes the helm at a critical moment as the Foundation seeks to accelerate its mission by complementing its aggressively funded research agenda with efforts to engage the nationwide and international patient, family and researcher community in the development of improved therapies for those living with Parkinson s today. Having co-founded MJFF with Michael J. Fox in 2000 and served as CEO until 2007 and Executive Vice Chairman until the present day, Brooks is a central architect of the Foundation s milestone-driven, innovative research model that has generated more than $1 billion to support Parkinson s research.
Longevity Acquisition Corporation Announces 4D pharma Joining Landmark Parkinson s Progression Markers Initiative
News provided by
Share this article
Share this article
NEW YORK, Dec. 21, 2020 /PRNewswire/ Longevity Acquisition Corporation (NASDAQ: LOAC) (the Company ), a publicly-traded special purpose acquisition company, announced today that on December 18, 2020, 4D pharma plc (AIM: DDDD) ( 4D pharma ), a pharmaceutical company leading the development of Live Biotherapeutic products ( LBPs ) - a novel class of drug derived from the microbiome, and a business combination target of LOAC, has joined the Parkinson s Progression Markers Initiative ( PPMI ) as an industry partner. PPMI is a landmark study sponsored by The Michael J. Fox Foundation to better understand Parkinson s disease and accelerate the development of new treatments.